From presumed benefit to potential harm - Hormone therapy and heart disease

New England Journal of Medicine

Volumn 349, Issue 6, 2003, Pages 519-521

  Herrington, David M ^a   Howard, Timothy D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENETIC POLYMORPHISM; HEART DISEASE; HORMONAL THERAPY; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; GENETICS; HORMONE SUBSTITUTION; METHODOLOGY; NOTE; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

CARDIOVASCULAR DISEASES; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RESEARCH DESIGN; RISK FACTORS;

EID: 0042208437     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMp038108     Document Type: Review

References (2)

1. Grady D. Postmenopausal hormones - therapy for symptoms only. N Engl J Med 2003;348:1835-7.
2. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-50.